Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse
A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherap...
Main Author: | Jeong Uk Lim |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2023-01-01
|
Series: | Tuberculosis and Respiratory Diseases |
Subjects: | |
Online Access: | http://e-trd.org/upload/pdf/trd-2022-0081.pdf |
Similar Items
-
Research Progress on Postoperative Adjuvant Therapy for Completely Resected Stage ⅠB Non-small Cell Lung Cancer
by: MA Shishi, et al.
Published: (2023-03-01) -
Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences
by: Fei Xu, et al.
Published: (2022-11-01) -
Recent Advances in Adjuvant Therapy for Non–Small-Cell Lung Cancer
by: Mi-Hyun Kim, et al.
Published: (2024-01-01) -
Case report: Adjuvant therapy with toceranib for an incompletely resected renal cell carcinoma with suspected pulmonary metastasis in a dog
by: Da-Eun Lee, et al.
Published: (2023-11-01) -
Negative Effect of Reduced NME1 Expression on Recurrence-Free Survival in Early Stage Non-Small Cell Lung Cancer
by: Dohun Kim, et al.
Published: (2020-09-01)